New data to be presented at the 2013 ASCO Annual Meeting show Active Biotech's commitment to oncology research

Lund, Sweden, May 16, 2013, Active Biotech (NASDAQ OMX NORDIC: ACTI) will present data from two of its oncology projects, the drug candidates tasquinimod for the treatment of prostate cancer and ANYARA for the treatment of renal cell cancer, at the scientific conference "2013 ASCO Annual Meeting" to be held in Chicago (USA) on May 31- June 4, 2013. Active Biotech's collaboration partner Ipsen will present two tasquinimod posters.

Active Biotech presentations include:
- (P3073) A randomized phase II/III study of naptumomab estafenatox plus IFN-gamma versus IFN-gamma in advanced renal cell carcinoma. R. Hawkins, M. Gore, Y. Shparyk, V. Bondar, O. Gladkov, T. Ganev, M. Harza, S. Polenkov, I. Bondarenko, P. Karlov, O. Karyakin, R. Khasanov, G. Hedlund, G. Forsberg, O. Nordle, T. Eisen. The study did not achieve its primary endpoint. However, in a subgroup analysis, the 25 % of patients with low/normal levels of base line IL-6 and expected anti-superantigen antibody levels, showed a statistically significant treatment advantage on both Overall Survival (OS) and Progression Free Survival (PFS). OS was 63.3 months for the ANYARA group vs. 31.1 months for placebo group (p=0.02, HR=0.59) and PFS 13.7 vs. 5.8 months (p=0.016, HR=0.62).

- (P5081) An Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod. A.J. Armstrong,  R. Kaboteh, M.A. Carducci, J-E Damber, W. M. Stadler, M.Hansen, L. Edenbrandt, G. Forsberg, O. Nordle, R. Pili, M. J. Morris. The Bone Scan Index (BSI) was prognostic for OS in mCRPC patients enrolled in the Phase II multicenter trial of tasquinimod and treatment with tasquinimod was associated with a decreased BSI progression rate. This study is co-sponsored by Active Biotech, Exini and Ipsen.

Ipsen presentations on tasquinimod include:
- (P5098) A Randomized, double-blind, placebo-controlled proof of concept study of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who experience response or stabilization during first-line docetaxel chemotherapy. K Fizazi, A Heidenreich, G Daugaard, J Bellmunt, N Germann, E Chetaille. This Phase II, multinational, randomized, double-blind, placebo-controlled proof of concept study is on-going. It is performed and sponsored by Ipsen. Patients with mCRPC will be randomly assigned (ratio 1:1) to receive tasquinimod or placebo. Randomization will be stratified by presence of visceral metastases and opioid analgesic use for cancer-related pain.